AL
Alzamend Neuro Inc
ALZN · NASDAQ
$1.94 +0.52% (+$0.01)
1M +21.25%
Market Cap $7.38M
P/E Ratio -
Div. Yield -
ROE 277.88%
Bulios Fair Price
$1.2
38.1% downside
Current Price
$1.94
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALZN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.27x
PEG N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 37.79%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 106.49%
ROIC 156.69%
Asset turnover 0.00x
Debt
100 /100
Low Int. coverage 546.20x
Debt/Equity 0.00x
Current ratio 3.01x
Stability
31 /100
Unstable Profitable years 0
Beta 0.19x
EPS volatility 28.87%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALZN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephan Jackman
Employees
6
Headquarters
Atlanta
Upcoming events
08 DEC
Earnings
Upcoming earnings report